#United States #New York #Actimab-A #Actinium Pharmaceuticals #targeted radiotherapies

Exciting Developments from Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc., a leader in the field of targeted radiotherapies, has recently made notable advancements in its development of Actimab-A. The New York-based company, listed under the NYSE American as ATNM, revealed these updates through a press release on August 14, 2026.

Key Patent Acquisitions and Manufacturing Improvements

The company's Actimab-A program has seen significant progress, especially in its intellectual property (IP) portfolio. Over the past year, Actinium has successfully secured various patents that bolster its position in the competitive market of cancer treatment. These patents expand the therapeutic uses of Actimab-A, particularly in addressing myeloid hematological malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Additionally, Actimab-A is being positioned for the treatment of solid tumor cancers through targeting tumor-resident myeloid-derived suppressor cells (MDSCs).

Actinium’s recent patent acquisitions include two United States patents: US 12,491,274, valid until October 15, 2043, focusing on sarcoma treatment, and US 12,539,340, expiring on October 31, 2043, for treating solid tumors either alone or in conjunction with checkpoint therapy. These acquisitions signify a crucial step forward, allowing Actinium to extend its anti-CD33 franchise beyond hematologic malignancies into solid tumors, leveraging the immunosuppressive roles of myeloid cells rather than directly targeting tumor cells.

Moreover, the company announced the issuance of additional patents for Actimab-A's use in low peripheral blast AML and combination therapy with venetoclax, reinforcing the growing capabilities of Actimab-A in diverse therapeutic strategies.

To further enhance its manufacturing process, Actinium has amended its Investigational New Drug (IND) application by incorporating a new manufacturer. This additional manufacturing partner will support studies conducted under the Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) as well as provide crucial supply capacity for future company-sponsored studies. This move is anticipated to augment Actinium's ability to advance Actimab-A through an expanded array of clinical trials set for the latter half of 2026 and into 2027.

NYSE American Listing Compliance Update

In addition to advancements in its Actimab-A program, Actinium Pharmaceuticals has also provided an update concerning its listing status on the NYSE American. The company announced that NYSE Regulation has accepted its compliance plan, which was submitted on June 18, 2026. The plan grants the company a maximum period through November 27, 2027, to regain compliance with the NYSE American continued listing standards.

During this plan period, Actinium's common stock will continue to be listed and traded on the NYSE American under the symbol ATNM. The company is expected to adhere to the stipulations outlined in its compliance plan to maintain its listing while NYSE Regulation staff will undertake periodic reviews of its compliance with these initiatives.

As previously noted, Actinium has faced challenges regarding compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. However, with strategic advancements and its commitment to regulatory compliance, Actinium is poised to navigate through this critical period.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals has long been a pioneer in developing targeted radiotherapies for cancer treatment, aiming to achieve favorable patient outcomes. The company adopts a biology-driven approach to create radiopharmaceuticals, focusing on minimizing toxicity to healthy tissues while enhancing therapeutic efficacy. With a diverse pipeline that includes candidates for solid tumors and hematologic malignancies, Actinium remains committed to driving innovation in cancer treatment. More information about Actinium Pharmaceuticals and its ongoing projects can be found on their official website, actiniumpharma.com.

Looking Forward

As 2026 progresses towards its conclusion, the advancements made by Actinium Pharmaceuticals mark a hopeful outlook for the company's future, particularly in the battle against cancer. With technologies and products that target the roots of malignancies while adhering to strict regulatory guidelines, Actinium stands at the forefront of innovation in the oncology sector.